此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Efficacy of Spinal Cord Stimulation in Chemotherapy-Induced Peripheral Neuropathy (CHEMOSTIM)

2026年5月6日 更新者:Assistance Publique Hopitaux De Marseille

Efficacy of Posterior Spinal Cord Stimulation in Chemotherapy-Induced Peripheral Neuropathic Pain: A Multicenter Randomized Crossover Trial

Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and debilitating side effect of many cancer treatments. It affects 28 to 48% of patients receiving chemotherapy. Symptoms include tingling, numbness, burning sensations, and pain mainly in the hands and feet. While CIPN often improves after chemotherapy ends, in some patients the pain persists and becomes chronic, severely impairing quality of life, sleep, and daily functioning.

Currently, no treatment has been shown to prevent CIPN. For patients with chronic pain, duloxetine is the only recommended drug, but its efficacy is limited. When standard medications fail, patients have very few options.

Spinal cord stimulation (SCS) is a well-established neurosurgical technique used to treat various forms of chronic neuropathic pain, including pain after surgery, trauma, or diabetes. In this procedure, thin electrodes are placed in the epidural space near the spinal cord and connected to a small implantable pulse generator. The electrical impulses delivered by the device modulate pain signals in the nervous system.

Preliminary case reports suggest that SCS may be effective in patients with CIPN, but no randomized controlled trial has yet established its value in this specific indication. The CHEMOSTIM study aims to fill this gap.

CHEMOSTIM is a multicenter, prospective, randomized crossover trial. All enrolled patients will undergo SCS implantation. Participants will then be randomized to receive either active stimulation first followed by sham stimulation, or sham stimulation first followed by active stimulation. In the sham phase, the device is implanted but switched off following a simulated programming session, so patients cannot tell which phase they are in.

The primary outcome is the proportion of patients achieving more than 50% pain reduction on a Visual Analog Scale (VAS) during the active stimulation phase compared to the sham stimulation phase, assessed at 4 months.

Secondary outcomes include changes in quality of life, anxiety and depression, sleep quality, medication use, individualized goal attainment, neurological examination, and nerve conduction studies. The study will also evaluate post-stimulation effects and complications.

Eligible patients are adults with chronic CIPN evolving for at least one year, with pain greater than 5/10 in the lower limbs, who have failed at least two lines of pharmacological treatment (antidepressants, anticonvulsants, topical agents, etc.) and whose indication for SCS has been validated by a multidisciplinary team following SFETD/SFNM guidelines.

研究概览

研究类型

介入性

注册 (估计的)

68

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Adult patient with chemotherapy-induced painful neuropathy (platinum salts, vincristine, taxanes, alkaloids, epothilone, thalidomide, etc.) evolving for at least 1 year
  2. Indication for spinal cord stimulation validated by a multidisciplinary team meeting according to SFETD/SFNM guidelines
  3. Resistance to pharmacological or topical treatment (failure of at least two therapeutic lines or intolerable side effects: anticonvulsants, antidepressants, capsaicin, etc.)
  4. Pain score > 5/10 on numerical scale in the lower limbs
  5. Patient able to understand and give informed consent to the protocol
  6. Patient affiliated to the French Social Security system
  7. Patient able to complete follow-up questionnaires

Exclusion Criteria:

  • 1. Contraindication to spinal cord stimulation:
  • Extensive laminectomy
  • Coagulopathy
  • Intercurrent infections
  • Psychiatric disorders

    2. Body Mass Index (BMI) > 40

    3. Life expectancy < 1 year

    4. Ongoing pregnancy

    5. Patient under guardianship or curatorship

    6. Patient already implanted with a spinal cord stimulation device

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Active stimulation first - Sham stimulation second
Participants receive active spinal cord stimulation (FAST mode, sub-perception) for 4 months, followed by sham stimulation (device switched off) for 3 months.
Sub-perception spinal cord stimulation delivered in FAST mode at 10% below perception threshold. The remote control is sealed and given to the patient with instructions not to use it.
假比较器:Sham stimulation first → Active stimulation second
Participants receive sham stimulation (device switched off) for 3 months, followed by active spinal cord stimulation (FAST mode, sub-perception) for 4 months.
The implanted device is switched off following a simulated programming session identical to the active phase (perception threshold verified, stimulation reduced to 80% of threshold, then switched off). Patients are unable to distinguish sham from active stimulation.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Proportion of patients with ≥50% pain reduction on Visual Analog Scale (VAS)
大体时间:4 months (end of first stimulation sequence)
4 months (end of first stimulation sequence)

次要结果测量

结果测量
大体时间
Global Impression of Change
大体时间:4 months and 7 months
4 months and 7 months
Anxiety and Depression (HADS)
大体时间:4 months and 7 months
4 months and 7 months
Sleep Quality (Pittsburgh Sleep Quality Index)
大体时间:4 months and 7 months
4 months and 7 months
Medication consumption
大体时间:4 months and 7 months
4 months and 7 months
Goal Attainment Scale (GAS)
大体时间:4 months and 7 months
4 months and 7 months
Device and stimulation-related complications
大体时间:7 months
7 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2029年3月1日

研究完成 (估计的)

2029年5月1日

研究注册日期

首次提交

2026年4月29日

首先提交符合 QC 标准的

2026年5月6日

首次发布 (实际的)

2026年5月12日

研究记录更新

最后更新发布 (实际的)

2026年5月12日

上次提交的符合 QC 标准的更新

2026年5月6日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅